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Abstract
Background: Influenza A viruses are major human and animal pathogens with huge economic and societal impact from
illness, hospitalizations, and deaths. Virus-like particles (VLPs) of influenza virus have been suggested as a vaccine candidate
offering improved safety and efficacy. To develop this concept further, we established a flexible platform to efficiently
generate different subtypes of mammalian-expressed influenza VLPs. Here we demonstrate that these mammalian VLPs
strongly resemble the authentic viruses in structure, particle size and composition of host factors, and even glycosylation of
viral antigens.
Methodology/Principal Findings: In this study, a mammalian VLP system was established by stable co-expression of four
influenza structural proteins (HA, NA, M1, and M2) in a Vero cell line. By replacing the surface glycoproteins of HA and NA,
we converted the H3N2-VLP subtype to H5N1-VLP. After centrifugation purification of conditioned media, the particle
morphologies, average sizes, and hemagglutination abilities of secreted VLPs were characterized, and the VLP constituents
were identified by LC/MS/MS. Protease protection assays demonstrated that specific cellular proteins that co-purified with
influenza virions were integrated into mammalian VLPs. The glycosylation profiles of mammalian VLPs as revealed by
deglycosylation assays were similar to that of progeny viruses produced from Vero cells. Vaccination of mice with 2.5 mg
and above of H5N1-VLP elicited H5-specific IgG1 antibodies and resulted in full protection against lethal infection with
homologous virus. These results provide compelling evidence that mammalian VLPs closely emulate the exterior of
authentic virus particles not only in antigen presentation but also in biological properties and should provide promising
vaccine candidates.
Conclusions/Significance: This flexible mammalian influenza VLP system offers a superior alternative to the conventional
reverse genetic vaccine platform without concerns over inadequate presentation of immune antigens or limitations
imposed by the manipulation of real viruses.
Citation: Wu C-Y, Yeh Y-C, Yang Y-C, Chou C, Liu M-T, et al. (2010) Mammalian Expression of Virus-Like Particles for Advanced Mimicry of Authentic Influenza
Virus. PLoS ONE 5(3): e9784. doi:10.1371/journal.pone.0009784
Editor: Charlotte Hauser, Institute of Bioengineering and Nanotechnology, Singapore
Received October 7, 2009; Accepted February 28, 2010; Published March 22, 2010
Copyright:  2010 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was financially supported by a National Science Council grant (NSC 95-2745-B-001-003) and the Summit Project from Academia Sinica. Also,
Core Facilities for Proteomics Research is supported by NSC 98-3112-B-001-023. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pwhsiao@gate.sinica.edu.tw
Introduction
Influenza infection is a major threat to human health and results
in significant morbidity and mortality worldwide. According to
World Health Organization estimates, seasonal influenza epidem-
ics influence 5,15% of the global populations annually and are
responsible for more than 3–5 million hospitalizations and about
250,000 to 500,000 deaths per year (http://www.who.int/
mediacentre/factsheets/fs211/en/index.html). Recently, in addi-
tion to the yearly circulating seasonal influenza variants caused by
antigenic drift, other influenza virus strains with pandemic
potential such as the highly pathogenic avian H5N1 or emerged
novel A/H1N1 pose greater threats than in the past (http://www.
who.int/csr/disease/avian_influenza/country/en/ and http://
www.who.int/ csr/don/2009_08_19/en/index.html) since they
have become better adapted to humans by reassortment. The most
efficient way of reducing the transmission of and the subsequent
huge economic loss caused by seasonal or pandemic outbreaks of
influenza is preventive vaccination. The manufacture of the
current licensed influenza vaccines, either in the form of a split
subvirion (disrupted, highly purified virus) or a subunit vaccine
(purified hemagglutinin, HA, and neuraminidase, NA), is abso-
lutely dependent on fertilized chicken eggs as a production
bioreactor. This method has substantial limitations since the
manufacturing capacity is restricted by the availability of eggs,
which may be insufficient to meet the urgent requirements for
vaccine during a pandemic [1,2]. In addition, these vaccines
induce antibodies primarily to the viral HA and are efficacious in
healthy adults, but display lower protective rates in high-risk
groups (e.g., the elderly) and may be poorly immunogenic in
young children. These problems are compounded once the wild
population of virus undergoes significant antigenic drift in the HA
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9784component [1,3,4,5,6]. Consequently, the protective immunity
elicited by inactivated vaccines is of too short a duration to protect
from newly developed influenza variants. Therefore, the develop-
ment of vaccines with cross-protective efficacy to allow a rapid
response to influenza evolution and/or to prolong the efficacy of
vaccination needs to be addressed.
Recently, the use of noninfectious virus-like particle (VLPs) that
self-assemble by spontaneous interactions of viral structural
proteins has been considered to offer good potential for advanced
vaccines for a wide range of viruses that cause disease in humans
[7]. It is worth noting that a VLP-based human papillomavirus
(HPV) vaccine produced in yeast system which is capable of
inducing protective immune response against the HPV responsible
for cervical cancer was approved for the market in 2006 [8].
Influenza VLPs expressed by recombinant baculovirus systems
that present multi-component antigens, including HA and matrix
1 (M1), with or without NA, and that are capable of inducing
cognate or innate immune responses against homologous or
heterologous strains of influenza virus, have been widely described
[9,10,11,12,13,14,15]. Alternatively, a further improvement in the
preparation of seasonal influenza vaccines licensed in Europe uses
reverse genetics in mammalian cell-based culture systems rather
than in eggs [6]. Using mammalian cell culture systems such as
Vero or MDCK cells as adaptive hosts for vaccine viruses has
several advantages, not only increasing the flexibility and
consistency of the manufacture process but also recovering the
host-dependent specific glycosylation of viral antigens which may
not be glycosylated properly in egg- or baculovirus-dependent
systems. In eukaryotic cells, protein glycosylation is involved in
correct folding or directing the cellular localization of newly
translated proteins and plays important roles in protein function.
Different glycosylation patterns underlie some of the differences
between various strains of the influenza virus. Generation of
mammalian influenza VLPs has previously been achieved by
transient coexpression of HA and NA proteins in human 293T
cells [16]. For vaccine production purposes, we included here not
only HA and NA but also the matrix proteins M1 and M2 in our
mammalian VLP expression system since both M1 and M2 have
equally critical roles in influenza virus assembly and budding
processes, suggesting their similar importance for mammalian
VLP budding efficiency [17,18,19,20,21,22]. The incorporation of
M1 and M2 into mammalian VLPs not only increased the VLP
production yield but also supplemented interior viral antigens,
which may provide highly conserved T-cell and B-cell epitopes to
fight homologous and heterologous viruses [23,24].
In light of the great threats posed by seasonal and pandemic
influenza infection, any improved means for the development of
effective and safe vaccine candidates is worthwhile pursuing. In
this study, we have developed a flexible platform for the efficient
production of mammalian influenza VLPs by simply co-
expressing four influenza virus proteins, HA, NA, M1, and
matrix 2 (M2) in Vero cells. We have successfully created mimics
of two different subtypes of virus by replacement of surface
antigens HA and NA. These noninfectious mammalian VLPs
mimic the authentic virions not only in their morphology and
functional HA but also other important constituents. The close
similarity of the glycosylation patterns of the viral surface
antigens (HA) seen between VLPs constructed by transformed
V e r oc e l l sa n da u t h e n t i cv i r u sw h i c hh a db e e ne x p a n d e di nV e r o
cells implies that these nonpathogenic mammalian VLPs have
similar antigenicity to wild virus particles. Taken together, these
findings suggest that this mammalian VLP system presents a
practical new approach to safe and effective vaccine production,
which has none of the drawbacks of the egg-based or the
baculovirus culture-based methodology, and is an alternative to
the conventional reverse genetics approaches used in influenza
vaccine manufacture.
Results
Establishment of mammalian system generating
influenza virus-like particles (VLPs)
In this study, we used mammalian cell culture-based
approaches to generate influenza VLPs. To stably transfect the
viral genes of HA, NA, M1, and M2 critical for VLP production
into cultured Vero or Vero E6 cell lines, we designed four gene
expression cassettes and placed these into two vectors as
illustrated (Fig. 1A). A tetracycline repressor gene and tet
operator-regulated gene expression cassette were also inserted
in the plasmid expressing M1 andM 2 ,g i v i n gt h ev e c t o rp C I 6 /
TO-M1-M2. By stable transfection of the M1–M2 vector into
Vero cells, we generated founder cells that would not express the
M1–M2 transgene until doxycycline (Dox) induction. Another
two tet operator-regulated, CMV promoter-driven expression
cassettes were inserted separately into the other plasmid carrying
HA and NA genes, giving the expression vector pCI4/TO-HA-
NA. After stable transfection of pCI4/TO-HA-NA vector into an
M1–M2 founder cell line, a mammalian-expressed VLP system
was established.
To verify that co-expression of all four viral genes was indeed
driven by the inducible promoter (CMV-TO), total cell lysates of
quadruple-transfected Vero cell line of H3N2 were analyzed by
Western blot with specific viral antibodies against H3, M1, and
M2 (Fig. 1B). As there is no available antibody to N2, we used RT-
PCR to confirm the expression of the N2 gene. The cellular
localization of H3 was also observed by confocal laser scanning
microscopy (Fig. 1D). The utility of this system as an alternative
platform to reverse genetics for vaccine development was shown
by the simple substitution of a separate plasmid carrying the HA
and NA genes of H3N2 with those of H5N1 (Figs. 1C and E). The
resulting quadruple H5N1-VLP cell line again co-expressed HA
and NA, this time of the H5 and N1 varieties. So far, we have
obtained two subtypes of quadruple Vero cell lines that generated
the putative H3N2- and H5N1-VLPs, respectively.
Morphology and antigen presentation of purified H3N2-
and H5N1-VLPs
To investigate whether the H3N2- and H5N1-VLPs assembled
and budded from the quadruple-transfectant cell lines, the media
surrounding Dox-induced cells were collected and purified by
cosedimentation in sucrose density gradient centrifugation. The
morphologies of mammalian VLPs purified from culture medium
of transfected cells were negative stained with 2% uranyl acetate
and compared to their reciprocal viruses propagated in Vero cells
using TEM (Figs. 2A and B). The VLPs displayed generally
spherical morphologies and densely stained cores. The spike
projections on the surface of VLPs were no different in appearance
to those on authentic influenza viruses. The HA and NA
glycoproteins on the surface of VLPs were immunogold labeled
with individual specific antibodies and counterstained with gold
spheres coupled to secondary antibodies (Figs. 2C and D).
Dynamic light scattering (DLS) determination of average
particle size of mammalian VLPs
To complement the morphology analysis by TEM, the average
sizes of secreted VLPs in native solution were estimated by DLS
assays. To be an effective vaccine, it has been proposed that
Mammalian VLP as Flu Vaccine
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of free antigens to the lymph nodes and induce strong responses in
dendritic cells (DC) for long-term protective purposes [25]. Laser-
based DLS can monitor changes in Brownian motion of
nanoparticles in solution, giving information related to the average
size and frequency distribution of particles. As shown in Fig 3, the
average diameters of H3N2- and H5N1-VLPs, as determined by
DLS, were 108.2617.9 nm and 125.6610.5 nm, respectively (at
pH 7.4, 25uC), and are comparable to the sizes obtained for their
reciprocal viruses (H3N2: 133.5615.4 nm and H5N1:
104.1612.4 nm). The size distributions of both subtypes of VLPs
ranged from 70–200 nm (95% CI), suggesting that the mamma-
lian VLPs were in the preferred size range for DC uptake and
promise to stimulate a potent immune response (Fig. 3). DLS will
Figure 1. Construction and cellular expression of influenza virus-like particles (VLPs) in mammalian cells. (A) Diagrams of mammalian
expression vectors of influenza VLPs. Indicated are the CMV constitutive promoter (CMV), tetracycline repressor gene (TetR), polyadenylation signals
(PA), CMV doxycycline (Dox)-inducible promoter (CMV-TO), chimeric intron (In), encephalomyocarditis virus internal ribosomal entry site (IRES), and
influenza genes (M1 and M2, matrix 1 and 2; HA, hemagglutinin; NA, neuraminidase). (B), (C) Expression of viral genes in selected quadruple VLP
producer cells. The total cell lysates were extracted from VLP producer cells without (2) or with (+) Dox induction, and then probed with respective
specific antibodies against HA, NA, M1, and M2 in Western blot assays. Expression of N2 was detected by RT-PCR. Molecular masses of expressed HA,
NA, M1, and M2 are indicated on the right. (D), (E) In vivo immunofluorescence staining of expressed viral proteins in VLP producer cells with
antibodies against HA and NA (red) as marked and counterstained with DAPI (blue).
doi:10.1371/journal.pone.0009784.g001
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VLPs by rapidly providing information on the whole population
of particles. Together, the DLS and TEM measurements of
mammalian VLPs were consistent and show the VLPs to be
of comparable size and morphology to native influenza viruses.
Identification of VLP composition and VLP-associated
cellular proteins
To verify the protein constituents of mammalian-expressed
VLPs, 10 mg of H3N2- and H5N1-VLPs were separated on a 7.5–
17.5% gradient gel, and stained with Coomassie blue (Fig. 4A and
Figure 2. Morphology and antigen presence determinations of purified mammalian VLPs. (A), (B) Secreted VLPs and virus were purified
by sucrose density gradient ultracentrifugation, negatively stained with 2% uranyl acetate, and observed by TEM at 100,0006magnification; pictures
of respective virus strains are shown below the VLPs. (C), (D) Immunogold electron microscopy of purified VLPs. The primary antibodies used are
shown below individual panels. Secondary antibody was goat anti-rabbit conjugated to 12 nm gold beads.
doi:10.1371/journal.pone.0009784.g002
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separate experiments (Fig. 4B and D). Besides the viral proteins
HA, NA, M1, and M2, we also observed a wide spectrum of minor
bands in the VLPs similar to the authentic viruses (Fig. 4A and C).
To identify the basic protein profiles of these VLPs, the more
evident protein bands (indicated by arrows in Fig. 4A and C) were
excised from the gels, subjected to in-gel trypsin digestions, and
analyzed by liquid chromatography-tandem mass spectrometry
(LC/MS/MS). The major VLP constituents identified by
searching against the NCBI database are shown as Tables 1 and
2. We found that HA and NA proteins of mammalian VLPs were
distributed in multiple gel slices in addition to the expected
locations shown in Table 1. This likely reflects the fact that they
are the most abundant proteins in VLPs and form HA and NA
protein oligomers (Fig. 4B and D). In addition, we identified
another 22 VLP-associated cellular proteins that are identical or
functionally analogous to those cellular proteins commonly found
in the interior or exterior of influenza virions [26]. Most of them
could be classified into functional groups including cytoskeleton
protein, extra cellular matrix (ECM) proteins, heat shock proteins,
annexins, tetraspanins, and glycolytic enzymes. It is worth noting
that we also identified several unique cellular proteins (listed in
Table 2) with very high Mascot scores, which are possibly involved
in VLPs biosynthesis. For real viruses, recruitment or encapsida-
tion of some cellular proteins into the virion may be a critical
behavior supporting the completion of the life cycle by some
specific interaction with viral proteins or RNA. However, in this
case, the mammalian influenza VLP has the components of viral
(by transfection) and cellular proteins (by recruitment) without
package of any viral genetic material. The cellular proteins
identified in our VLPs might be actively involved in the normal
virus life cycle, especially during virus assembly and budding from
the host cells.
To characterize the functionality of the HA spike on
mammalian VLPs, hemagglutination assays were performed
(Fig. 4E). VLP preparations reacted with 0.75% guinea pig
erythrocytes had significant hemagglutination activities, with titers
of 2
7 for H3N2-VLPs and 2
6 for H5N1-VLPs in samples
containing 3.5 mg of VLPs. Both H3N2 and H5N1 viruses of
same amount as VLPs were at similar titers (2
7) of HA activity.
This result suggests that the HA spikes compassing around the
surface of mammalian VLPs are in a native orientation and
function as those of active authentic viruses.
Confirmation of cellular proteins associated and
incorporated into mammalian VLPs
Following proteomic identification of incorporated cellular
proteins, several viral and associated cellular proteins were further
Figure 3. Dynamic light scattering (DLS) measurements of particle sizes and distributions of mammalian VLPs in solution. Average
particle diameters of H3N2-VLPs (A), H3N2 virus (B), and H5N1-VLPs (C), and H5N1 virus (D) in phosphate buffer (pH 7.4), at 25uC. Two representative
determinations of different batches of VLPs and virus are shown as red and green lines. The size distribution of VLP populations ranged from 70 to
200 nm with a 95% confidence interval (CI).
doi:10.1371/journal.pone.0009784.g003
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9784Figure 4. Characterization of purified mammalian VLPs. The total proteins of purified H3N2-VLPs and H3N2 virus (A) and H5N1-VLPs and
H5N1 virus (C) were resolved by SDS-PAGE in a 7.5–17.5% gradient gel and stained with Coomassie blue. Molecular masses of protein markers are
shown on the right. Each relevant band, as marked with an arrow and a number, was subjected to LC/MS/MS analysis to identify its composition. The
Mammalian VLP as Flu Vaccine
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out the possibility that identified proteins may be due to non-
specific contamination such as co-purification of microvesicles or
exosomes with VLPs, the mammalian influenza VLP preparations
were subjected to a protease protection assay that has been shown
to efficiently remove microvesicles from HIV-1 virion preparations
[27,28]. After trypsin incubation, H5N1-VLPs were re-purified by
sucrose cushion ultracentrifugation and subjected to Western blot
analysis with antibodies against HA, NA, M1, M2, b-actin,
tubulin, annexin A2, and clathrin (Fig. 5A). Both HA and NA
proteins were lost from the VLPs after trypsin digestion,
demonstrating that these proteins were located on the outside of
the membrane envelope, integral and attached to the VLP surface.
Most co-purified contaminants were eliminated by the protease
digestion. However, several representative cellular proteins
expected to be inside the virion such as actin, tubulin, and
annexin A2 were still found to be present in the protease-digested
VLPs, which indicates that these cellular proteins were specifically
incorporated into the structure of VLPs (Fig. 5A). In contrast, a
unique cellular protein identified in this study, clathrin heavy
chain, an important component of the clathrin-coated pits
mediating the endocytosis of many receptors, ion channels,
transporters, and other transmembrane proteins as well as various
soluble macromolecules and viruses, was lost following protease
treatment (Fig. 5A) [29,30]. This finding raised two possibilities:
Firstly, clathrin is associated with contaminants rather than the
VLPs, or secondly, clathrin is indeed incorporated into VLPs but is
exposed on the surface like HA and NA. To resolve this issue, we
used immunogold labeling to look for the presence of clathrin on
the surface of intact, undigested VLPs (Fig. 5B). This assay did
show clathrin staining on the surface of intact VLPs, just as for HA
and NA (Figs. 2C and D).
Generally, the results of two independent LC/MS/MS analyses
of H5N1- and H3N2-VLPs and Western blotting in this study
resemble the reported proteome of influenza virus [26], which
suggests that the assembly of influenza VLPs shares much
similarity with real virus assembly and escape. Taken together,
these data confirm that the mammalian-expressed influenza VLPs
are very similar to the authentic viruses, a considerable advantage
to their use in further vaccine development.
Glycosylation profiling of influenza VLPs
Glycosylation of viral surface antigens is critical for immune
recognition, receptor binding, inflammation, and pathogenicity,
and therefore has a major influence on the efficacy of vaccine
antigens [31,32]. For example, the common phenomenon of
amino acid substitutions of the viral HA due to egg-adaptation and
the consequent altered glycosylations severely affect the antige-
nicity of influenza virus [33]. As demonstrated by N-glycan
footprinting analyses of HA, the use of different cell lines for
replication of the same virus results in different N-glycosylation
patterns on HA, which can be attributed to host-mediated changes
in the amino acid sequence and potential glycosylation sites of HA,
further influencing the antigenic properties of manufactured virus
[34,35,36]. Therefore, the glycosylation status of HA and NA
antigens in the VLPs were assessed to look for any change that
would affect the antigenicity and immune response of a VLP-
based vaccine. We compared the N-glycosylation patterns of
H3N2- and H5N1-VLPs produced from Vero cells to the glycan
profiles of authentic viruses by performing deglycosylation assays
with N-endoglycosidases PNGase F and Endo-H. PNGase F can
remove all types of N-linked oligosaccharides from glycoproteins
such as complex, hybrid, and high-mannose types, whereas Endo-
H cleaves the chitobiose core of high-mannose and hybrid
oligosaccharides from N-linked glycoproteins. As shown in
Figure 6A, most of the modified HA and NA (labeled as
HA1**+NA** and HA2**) in purified H5N1-VLP was seen as
two major bands in the SDS-PAGE gel before degylcosylation
(lane 1); their apparent molecular masses were around 56 and
30 kDa, respectively (Fig. 6B and C, lanes 1). After treatment of
H5N1-VLPs with PNGase F, HA1, HA2, and NA bands increased
their mobility to molecular masses of 40, 27, and 52 kDa,
respectively (Fig. 6A, B, and C, lanes 2), demonstrating that the
two predominant viral surface antigens were mainly glycosylated
by N-linked oligosaccharides. Of note, one form of NA marked as
(p) in Fig. 6C whose mobility was not changed by reaction with
both enzymes suggests NA may have other types of post-
translational modification. When the glycosylated HA from
H5N1-VLP was treated with Endo-H, the deglycosylation reaction
was only partial; therefore the original bands and the Endo-H
digested residue bands marked as (#) of HA1 and HA2 can be
seen simultaneously (Fig. 6B, lane 6). However, the HA of H5N1
virus propagated in Vero cells was resistant to Endo-H digestion,
suggesting the glycans linked to the viral HA are complex type
(Fig. 6B, lane 8). The partial sensitivity of HA in H5N1-VLPs to
Endo-H may be a result of hybrid glycan chains as the
overwhelming expression of viral protein may lead to incomplete
glycosylation. However, as the great majority of NA can be
deglycosylated by Endo-H, the NA proteins of H5N1-VLP may
possess more high-mannose than complex glycans (Fig. 6C, lane
4). In parallel, the deglycosylation assays were performed on
H3N2-VLPs (Fig. 6D). With H3 glycoprotein, incubation with
Endo-H or PNGase F reduced the molecular mass by 16 kDa or
by 25 kDa, respectively, suggesting a higher content of high-
mannose or hybrid types than complex type in the H3 glycan pool
(Fig. 6D, lanes 2–3). Our results suggest that VLPs generated from
this platform will have similar glycosylation profiles to the
authentic viruses that result from infection in the same host
species. Collectively, the mammalian VLPs resemble the real
viruses in particle size, morphology, protein composition, and
glycosylation profiles and therefore offer great potential as safe and
effective influenza vaccine antigens.
Humoral immune response of VLPs
To investigate the vaccine effect of mammalian expressed VLPs,
we vaccinated mice with VLPs without adjuvantation and
analyzed the antibody response and protection from viral
infection. Mice (BALB/c; n=12) were vaccinated twice (day 0
and 21) via intramuscular injection with purified H5N1-VLP or
inactivated whole virus of H5N1-pseudotyped vaccine strain
(recombinant H5N1 engineered by reverse genetics) at two
antigen doses (2.5 mg and 10 mg). Blood samples were collected
identified viral protein bands of H3N2- and H5N1-VLPs (marked with parentheses in panels A and C) confirmed by Western blot analyses with relevant
specific antibodies for H3N2-VLPs and virus (B) and for H5N1-VLPs and virus (D). The relative abundances of HA and NA, quantified by Chemigenius 2
(SYNGENE, Frederick, MD) and GeneTools (version 3.07) software, were 4:1 for H3N2-VLPs and 3:2 for H5N1-VLPs. The HA protein attributes to 12.8%
and 18% of total proteins in H3N2- and H5N1-VLPs, respectively. (E) Assessment of HA function by hemagglutination assay. The amounts of
mammalian VLPs or virus used are indicated, in a twofold serial dilution. TNE (buffer of VLPs) and PBS were included as the negative controls in the
hemagglutination assays.
doi:10.1371/journal.pone.0009784.g004
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PLoS ONE | www.plosone.org 8 March 2010 | Volume 5 | Issue 3 | e9784to analyze humoral immune response before primary (day -1) and
after immunizations (day 14 and 35) (Fig. 7A). Sera were tested for
influenza virus-specific IgG antibodies by ELISA against baculo-
virus produced H5 glycoprotein, or mammalian expressed H5N1-
VLP and H3N2-VLP (Fig. 7B). Mice vaccinated with H5N1-VLP
showed a robust response of IgG antibodies against H5 protein
and H5N1-VLP. The ELISA titers of both antigen doses against
H5 protein and H5N1-VLP were higher than 1:200,000. By
contrast, their titers against H3N2-VLP were insignificant
(,1:25,000). This suggests that H5N1-VLP was highly immuno-
genic, stimulating highly specific antibodies against the H5
epitopes. Whole virus vaccine resulted in ELISA titers of
approximately 1:100,000; while being highly immunogenic, the
H5-specific titer was considerably lower than with the VLP
vaccine (Fig. 7B). However, ELISA titers for VLP vaccine group
reduced to the level of whole virus vaccine group when whole virus
was used as ELISA antigen (Fig. 7C). This suggests that the
immunity of H5N1-VLP was more potent and specific to H5
glycoprotein, which could stem from the higher HA content in the
VLPs as compared to the one in the viruses. The specificity of the
VLP-induced antibody was further accessed by Western blotting
against all proteins of VLP and the virus. Indeed, the IgG
antibodies detected only signals corresponding to the H5
glycoprotein and M1 in the VLP and virus (Fig. 7D, left). The
lack of signal detecting other host proteins in this experiment
indicated the VLP was as ‘‘clean’’ as the inactivated split virus and
subunit vaccines, and predominantly immunogenic toward the
HA glycoprotein.
The IgG antibody isotypes distribution elicited by vaccination
is indicative of the type of T cell immune response, as subsets of
antigen-specific helper T cells regulate the production of different
IgG isotypes via secreting different cytokines. The IgG1 isotype
in mice is believed to signal a Th2 response, whereas the IgG2a
isotype indicates more of a Th1 response. ELISA test was further
used to measure the class and IgG isotypes of antigen-specific
antibodies in response to the VLP and whole virus vaccines. As
shown, the antibodies induced by VLP were predominantly IgG1
isotype, much less in IgG2a, and low or undetectable in IgG2b
and IgA (Fig. 7E, left). By contrast, the antibodies induced by
whole virus vaccine were mainly IgG2a, less in IgG1, and
negligible in IgG2b and IgA. These results suggest that
mammalian VLP vaccine at the two antigen doses induced
primarily a Th2 response, whereas whole virus vaccine
stimulated a mixed Th1/Th2 response with Th1 more dominant
at higher antigen dosage.
Vaccine induced hemagglutination-inhibition (HI) activity
and protection against viral infection
The HI assay is the most widely accepted serological test for
influenza immunity and is the gold standard measure of functional
HA-specific antibodies after vaccination. The serological criteria
currently used for approval of pandemic vaccines in the US are
based on seasonal influenza vaccines, with seroconversion (i.e. a
minimum 4-fold rise in HI titer) rate .40% and seroprotection
(i.e. HI titer .1:40) rate $70% in adults younger than 65.
Antibodies elicited by each vaccine candidate were evaluated for
their ability to inhibit the VLP-induced agglutination of guinea pig
red blood cells (Fig. 7E). After the second dose (day 35), the
seroprotective HI titers were induced in 83.3% of mice that
received 2.5mg and 10 mg VLP vaccine with mean HI titer
reaching about 1:60 (Fig. 7F). When the antigen dose of VLP
vaccine was decreased to 0.3 mg and 1.5 mg, the reciprocal
seroprotective rate dropped to 12.5% and 25%. Seroprotective
rates of corresponding whole virus vaccine were 75% and 87.5%,
respectively, in analogous experiments.
All mice vaccinated with VLP vaccine, whole virus vaccine or
mock control were challenged intranasally with a predetermined
lethal dose of H5N1-pseudotyped recombinant virus to evaluate
the protective efficacy of each vaccine candidate. All mice which
received 2.5 mg and 10 mg VLP vaccine survived after the viral
challenge, in contrast to the mock control mice that all died within
7 days after infection (Fig. 8A). Lower dose (0.3 mg and 1.5 mg) of
VLP vaccine compromised the survival rate (50% and 25%,
respectively), which is consistent with a lower seroprotection rate.
Whole virus vaccine (2.5 mg and 10 mg) resulted in protection
against the viral challenge; the exception was one mouse in the
2.5 mg dose group that lost .30% body weight (Fig. 8B). Body
weight and temperature changes of test mice were indicative illness
and mice vaccinated with high-dose VLP and whole virus vaccine
returned to their original weight by day 13 post-challenge (Fig. 8C,
D), a result consistent with the survival outcome. However, mice
vaccinated with low-dose VLP had more prominent weight loss
and temperature decrease; nevertheless some of the survivors
recovered at later time.
Table 2. Unique cellular proteins identified by LC/MS/MS with high Mascot scores in mammalian VLPs.
Protein Name Mass (Da)
Protein band numbera
H5N1/H3N2* Mascot score
b Sequence coverage (%)
c
clathrin heavy chain 1 (Cytoplasmic vesicles formation 192276 1 3242 63
Spectrin (interact with actin)
Beta (non-erythrocytic)
274472 1 1146 35
Plexin B2 (interact with cytoskeleton) 203451 1 757 26
Smilar to CD109 161515 1 738 23
Prostaglandin F2 receptor negative regulator 116885 2/2 1035/136 44/18
Na+/K+-ATPase alpha 1 112838 3/3 1266/452 42/29
Tumor rejection antigen (gp96) 1 92555 3/3 1016/614 52/60
Flotillin I 47384 9 1048 68
aExcised protein bands were numbered as indicated by arrows 1–11 of Fig. 4A and C.
bFor this search a Mascot score $25 is significant (p.0.05).
cSequence coverage is based on peptides with unique sequence.
*The band number, Mascot score, and sequence coverage of cellular proteins both identified in H5N1- and H3N2-VLPs were signalized as A/B.
doi:10.1371/journal.pone.0009784.t002
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In this study, we have established a platform to generate
mammalian influenza VLPs by the directed expression of four
viral structural proteins (HA, NA, M1, and M2). We have also
demonstrated the flexibility of this approach by exchanging the
surface antigens of HA and NA to generate VLPs mimicking two
subtypes of influenza (Figs. 2 and 4). When examined by TEM, the
VLPs were found to closely resemble influenza virus in size,
particle morphology, and fine structure of the surface spikes (Figs. 2
and 3). LC/MS/MS analyses and protease protection assays
revealed that the cellular constituents specifically present in
authentic virus were also incorporated into the mammalian VLPs,
which implied that the particular interactions between host
proteins and viral proteins involved in the biosynthesis of VLPs
probably reflected similar processes during virus assembly and
Figure 5. Specific integration of cellular proteins in influenza VLPs. Purified H5N1-VLPs were either mock-treated (Untr.) or digested
overnight with typsin (Prot.) followed by purification with a 20% sucrose cushion. Mock-treated VLPs (lane 1) or typsin-treated VLPs (lane 2), 2.5 mg
each, were further analyzed by Western blotting with antibodies against the indicated proteins including HA, NA, M1, M2, b-actin, tubulin, annexin
A2, and clathrin (A). Molecular weight markers are marked on the left. (B) Immunogold labeling of clathrin on the surface of purified VLPs. Secreted
VLPs purified from conditioned medium were immunogold labeled with antibody against clathrin, negatively stained with 2% uranyl acetate, and
observed by electron microscopy (100,0006magnification).
doi:10.1371/journal.pone.0009784.g005
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glycosylation profiles of HA and NA spike in mammalian VLPs
were examined by N-deglycosylation (Fig. 6). In both cases, the
glycosylation profiles of HA were highly similar to that of influenza
virus replicating in the Vero cells. Taken together, all these data
demonstrate that VLPs produced by this mammalian cell-based
system are a promising vaccine candidate.
Recently, clinical trials of HPV VLPs have led to FDA approval
of the vaccine [37,38]. Furthermore, influenza VLPs produced in
baculovirus systems have shown promise as safe and high-yielding
vaccines against influenza infection in preclinical animal models
[9,10,11,12,13,14,15,39]. Clinical studies for baculovirus-ex-
pressed influenza VLPs are currently being undertaken. In this
study, we demonstrate that vaccination with mammalian
expressed VLPs provided full protection against lethal infection
with the homologous strain at doses as low as 2.5 mg VLP (0.45 mg
HA) using two dose regimen in BALB/c mice. All these successes
indicate that the VLP-based vaccine approach is an attractive
alternative to replace or complement conventional inactivated
virus vaccines or subunit vaccines with improved safety and
efficacy, especially for children and the elderly.
In this study, we successfully applied a mammalian system to
produce influenza VLPs on a preclinical scale by stable co-
expression of four viral proteins. Typically, our pilot production in
a 3 L-scale microcarrier system yielded an average 1.2 mg/L
medium of mammalian VLPs after purification. Each inoculation
of 3 L culture attained 10
9 cells and could be induced to
continuously express VLPs three times. This is also the first report
to reveal, as confirmed by SDS-PAGE analysis, the proteome of
mammalian VLPs with sufficient quantities of HA and NA
proteins, including their further characterization by deglycosyla-
tion, hemagglutination assays, and immunization response.
Our proteomic analysis and protease protection assays of the
secreted VLPs revealed that 22 cellular proteins associated with
authentic virus of H1N1 were specifically incorporated into
mammalian H3N2 and H5N1 VLPs (Table1 and Fig 5). Among
these proteins, tubulin, actin, annexins, enolase, GAPDH, gamma-
glutamyltransferase, and HSP 27 have been demonstrated to be
derived from lipid raft by proteomic analysis in previous studies
[40,41,42,43,44]. Correct assembly and budding of influenza virus
requires cooperative action by multiple viral proteins with the lipid
bilayers and genomic RNA as well as host proteins [45,46]. In
VLP systems, except for the interactions involved in viral RNAs
and capsid proteins, the events related to virus particle release are
thought to be highly similar to real virus assembly and release. A
number of the proteins identified in mammalian influenza VLPs
shed light on their roles in the influenza virion during assembly/
budding stages of the infection process. The resemblance between
VLP proteome and virus cellular proteins also suggests that the
budding behaviors and constituents of mammalian VLPs are very
similar to those of authentic viruses. Thus, VLPs expressed from a
mammalian cell-based system constitute a non-pathogenic pseu-
dovirion with virus-like properties and hold great promise as a
vaccine candidate.
Apart from those common proteins identified in virion and
VLPs, we found several unique VLPs-associated cellular proteins
with very high Mascot scores in LC/MS/MS analysis. For
instance, clathrin was specifically incorporated by binding to the
exterior membrane of VLPs (Fig. 5). So far, it remains unclear why
clathrin, an endocytosis mediator protein, was specifically
associated with secretory influenza VLPs, though this discovery
may have implications for the route of VLP biosynthesis and for
the late stage of virus assembly and budding. Further experiments
need to be designed for an explanation of this role.
The present study demonstrates, for the first time, the efficacy
of VLPs created by a mammalian expression system as a new
influenza vaccine. The full protection of mammalian VLP
vaccine correlated well with functional antibody responses (HI
assay), which is the licensure criterion accepted for yearly
interpandemic vaccines. The presence of numerous cellular
proteins integrated into mammalian expressed VLP may raise
concerns of autoimmunity. Both Vero and Vero E6 cell lines are
currently considered as the most widely acceptable cell substrate
by regulatory authorities to produce a wide range of viruses for
human vaccine production, including influenza, polio virus,
rabies virus, smallpox, vesicular stomatitis virus, herpes simplex
virus and rotavirus. Currently, the WHO recommends only the
use of Vero cells to prepare viruses for vaccine production by
reverse genetics [47]. For this reason, we chose Vero and Vero
E6 cell lines rather than any other human or non-human
mammalian cell lines to produce VLPs. In fact, our studies
demonstrate that vaccination in mice with VLP without adjuvant
formulation elicited high-titer antibodies only against HA but not
other proteins (Fig. 7). Vaccinated mice survived perfectly with
two doses of VLP vaccines at 2.5 mga n d1 0 mgl e v e l sv i a
intramuscular immunization, and they all survived the subse-
quent lethal viral challenge. No adverse effects were found before
and after viral challenge throughout the 56-day experiment. We
should note that the humoral immune response elicited by
mammalian expressed VLPs is different from that of baculovirus-
derived VLPs, suggesting a distinction between the two forms of
VLPs. Such difference may be attributed to the glycosylation
profile, host protein contents, the overall particle structure that
present antigens, or other factors.
In addition, this report focused on the characterization of
advanced mammalian VLPs and the methodology of their
production. We nonetheless propose that this will be a promising
new agent to address influenza infection because 1) we have
demonstrated here the preclinical-scale production of mamma-
lian VLPs; 2) we have shown, by a simple exchange of surface
antigens, that our development platform is flexible and can
shorten the lead time for adjusting the match of vaccine
specificity against the circulating strains of viruses; 3) this
approach for the expression of VLPs will alleviate safety
restrictions and bottlenecks associated with dependence on live
viruses; and 4) this methology will permit rapid and scaleable
production, independent of a reliance on egg availability for
vaccine manufacturing.
Figure 6. Glycosylation profiling of HA and NA in mammalian VLPs. Mock-treated and deglycosylase-treated proteins of H5N1-VLPs
were separated by SDS-PAGE, stained with Coomassie blue (A), and further analyzed by Western blotting using antibodiesagainst H5 (B) and N1
(C). In parallel, mock-treated and deglycosylase-treated proteins of H3N2-VLPs were analyzed by Western blotting using the antibody against
H3 (D). Untreated and deglycosylase-treated proteins of respective VLPs and virus are compared in panels B and D. Glycosylated HA1, HA2, NA,
and H3 are denoted as HA1**, HA2**, NA**, and H3**, respectively. # represents glycosylated proteins harboring a residue moiety of
complex-type glycans sensitive to PNGase F, but not Endo-H. p represents unknown posttranslational modifications on the NA of
H5N1-VLPs.
doi:10.1371/journal.pone.0009784.g006
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Cells, plasmids, and antibodies
Vero cells were obtained from the Bioresource Collection and
Research Center, (Hsinchu, Taiwan) and maintained in minimal
essential medium (HyClone, South Logan, UT) supplemented with
10% fetal bovine serum (Gibco, San Diego, CA) in a humidified
incubator at 37uC with 5% CO2. The cDNAs of M1 and M2
derived from the sequences of influenza A/Taiwan/083/2006 virus
were cloned into the backbone modified from pcDNA6/TR
(Invitrogen, Carlsbad, CA) linked by IRES separately into a single
eukaryotic expression vector to give the plasmid pCI6/TO-M1-M2
(Fig. 1A). The cDNAs of HA and NA were synthesized sequences
based on the distinct virus strains of A/Taiwan/083/2006 and A/
Hanoi/30408/2005(H5N1) (a kind gift from Dr. Po-Huang Liang
at the Institute of Biological Chemistry, Academia Sinica) optimized
for mammalian codon usage and further cloned into expression
vectors as illustrated for pCI4/TO-HA-NA (Fig. 1A). For the
mammalian H3N2- and H5N1-VLPs producer cells, the plasmid
pCI6/TO-M1-M2 was stably transfected into Vero cells to derive a
founder cell line, which was further transfected with HA-NA
expression vectors to obtain the quadruple co-expression cell line
with HA, NA, M1, and M2 proteins. To confirm the gene
expression of N2 in the H3N2-VLP producer cell line, total RNAs
were extracted separately from cells with and without doxycycline
(Dox) induction and RT-PCR assays were performed using a
primer pair corresponding to the internal sequence of the N2 gene.
These primers were N2-F, 59-ATTAGGCT TTCCGCTG-
GTGGGGACAT-39 and N2-R, 59-GCATTCTGACTCCTGG-
GTCCTGA GGATT-39. Expression of the proteins was confirmed
by Western blot analyses and immunofluorescence staining as
follows. QuadrupleVLP-expression cellswereinduced withDox for
48 h, or left untreated as a control. The cells were then fixed in 4%
paraformaldehyde for 10 min and immersed in 0.05% Triton-X
100 for 1 min. After blocking with 1% gelatin, the cells were
incubated with distinct primary specific antibodies, followed by
incubation with goat anti-mouse or goat anti-rabbit IgG conjugated
with Cy3 dye. Fluorescence images were acquired by confocal
microscopy (LSM 510 META NLO DuoScan, Carl Zeiss, GmbH).
The antibodies used in this study were polyclonal: H3 (ab20084),
N1 (ab21305), M1 (ab20734), annexin A2 (ab41803), and clathrin
(ab21679) from Abcam (Cambridge, MA), b-actin (sc-1616-R) from
Santa Cruz Biotechnology (Santa Cruz, CA), and monoclonal: M2
(ab5416), and tubulin (ab6160) from Abcam and H5 (MCA2660,
used for IFA) from AbD Serotec (Raleigh, NC). Rabbit polyclonal
antibody against H5 used for Western blotting was provided by Dr.
Che Ma (Genomics Research Center, Academia Sinica).
Microcarrier culture and purification of mammalian VLPs
To scale up the cultivation of VLP producer cells, 60 g
microcarriers (HyClone) and cells (about 2610
8) were added to a
3 L spinner flask (BellcoGlass, Vineland, NJ), stirred at around
35 rpm with a pendant glass ball, and maintained in minimal
essential medium supplemented with 10% fetal bovine serum in a
humidified incubator at 37uC with 5% CO2. After 7 days
cultivation, the cells had attached to the surface of the collagen-
coated microcarrier and grown to confluence. For VLP expression
and secretion from cells, the culture medium was removed and
replaced with serum-free medium (SFM4MegaVir, HyClone)
containing 1 mg/mL Dox to begin induction.
After Dox-induction for 72 h, conditioned medium of VLPs
producer cells was harvested, filtered with 0.45 mm Stericap,
concentrated by Vivaflow 50 (Sartorius Stedim Biotech, Go ¨ttin-
gen, Germany), and then layered onto a 30% sucrose-TNE
(10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EDTA)
cushion. Following centrifugation at 112,6006g for 2 h at 4uC
in a Beckman SW28 rotor (Beckman Coulter, Fullerton, CA), the
resulting pellet was resuspended in TNE buffer, and further
purified over a 20–30–60% sucrose gradient (112,6006g, 2 h at
4uC). Finally, the banded VLPs were collected, dialyzed with TNE
buffer overnight, and stored at 280uC. To analyze the protein
constituents of purified VLPs, the samples quantified by Quant-iT
Protein Assay Kit (Invitrogen) were mixed with La ¨mmle SDS-
PAGE sample buffer, boiled for 5 min, and separated in a 7.5–
17.5% gradient gel.
Immunogold electron microscopy of purified mammalian
VLPs
Sucrose gradient purified VLPs of 1 mg were adsorbed onto
formvar/carbon-coated nickel grids (Electron Microscopy Scienc-
es, Fort Washington, PA). After a 2 min wash with TBS buffer
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl), the sample was
blocked with 1% BSA in TBS for 1 h. Primary antibody (10 mg/
mL) was diluted in 1% BSA/TBS and adsorbed onto the grid for
1 h at room temperature. Following three washes with TBS,
secondary gold-conjugated antibody was added for 1 h at room
temperature. The grids were then washed twice with TBS, fixed
with 1% glutaraldehyde, washed with water, and negatively
stained with 2% uranyl acetate for 30 sec. The images of stained
mammalian VLPs were captured using a Hitachi H-7000
transmission electron microscope.
Dynamic light scattering (DLS) determination of particle
size
Stock solutions of mammalian VLPs were diluted to 0.1 mg/
mL in 20 mM phosphate buffer at pH 7.4, passed through 0.45-
mm filters, and analyzed on a Nano ZS particle-size analyzer
(Malvern Zetasizer, Malvern Instruments Ltd, UK). For each
sample analyzed by DLS, two consecutive measurements were
taken on a single sample and measured with a light-scattering
data collection time of 60 s. The accompanying software
(Nanov510) was used to convert the intensity-based measure-
ment to a size distribution based on the number of particles in
each size class, and was presented as a diagram of curves
Figure 7. Humoral immune response of mammalian VLPs. (A) Regimen of prime and boost vaccination was followed by viral challenge. IM0, IM1,
and IM2 represent the mouse serum collected before immunization (day -1), and 14 days after priming, and boosting, respectively. (B) The antigen-specific
IgGantibodiesfromtheserumofeachmousegrouptakenatIM2wereassayedagainstdistinctantigensofH3N2-VLP,H5protein(recombinantbaculovirus
expressed), and H5N1-VLP (same as the immunization antigen) by ELISA after vaccination of H5N1-VLP or inactivated whole virus (IWV). Groups of mice
(n=8–12) were either intramuscularly immunized with 2.5 mga n d1 0mg dose of VLPs, or IWV, as marked. The dilution of used serum samples in the ELISA
assays are labeled at the top. H3N2-VLPs containing all the host cell proteins integrated into the VLP antigen but with different subtype of HA and NA was
used as negative control, whereas the baculovirus-produced H5 protein constituted the positive control. The employed amounts of coating antigens are
shown. (C) ELISA of serum IgG antibodies induced by H5N1-VLPs or IWV vaccines against H5N1 virus as ELISA antigen. (D) Western blot analysis of mice
serum IgG antibodies elicited by either H5N1-VLP (left panel) or IWV (right panel) vaccines. The used antigens and individual amounts are indicated att h e
top of panels. (E) The specific IgG isotype and IgA elicited by VLPs and IWV vaccines were assayed using H5N1-VLP as ELISA antigen. (F) HI titer of each
vaccinated mouse; mean values of the same group are plotted. HI titer of 40 was set as threshold of seroprotection.
doi:10.1371/journal.pone.0009784.g007
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under the curve was proportional to the numbers of VLPs or
virus detected in the relevant size range. The average diameters
of VLPs or virus were then calculated as the mean size of particle
population 6 standard deviation (SD) of three independent
experiments.
Protease treatment of mammalian VLPs
Purified H5N1-VLPs equivalent to 50 mg of proteins were
incubated for 18 h at 37uC with or without 20 mg of MSG-Trypsin
(G-Biosciences, St. Louis, MO) in buffer containing 20 mM Tris-
HCl (pH 8.0) and 1 mM CaCl2. The treated and untreated VLPs
preparations were separately diluted to 7 mL with TNE buffer
containing 30 mM PMSF (Sigma, St. Louis, MO), concentrated
through a 20% sucrose cushion by ultracentrifugation (200,0006g,
2 h at 4uC in a Beckman SW41Ti rotor) and then subjected to
Western blot analyses.
Deglycosylation of mammalian VLP proteins
Purified VLPs equivalent to 10 mg of proteins were denatured
by heating for 10 min at 100uC in the presence of 0.5% SDS and
40 mM DTT. Next, either PNGase F or Endo-H (New England
Biolabs, Ipswich, MA) was added and the mixture incubated for
1 h at 37uCi n1 6G7 or G5 reaction buffers (New England
Biolabs). Subsequently, samples were subjected to protein gel
electrophoresis and Western blot analyses.
Figure 8. Vaccine Protection against lethal-dose challenge of H5N1 virus. At day 42, vaccinated mice were challenged intranasally with a
lethal dose (100 LD50) of recombinant H5N1 (NIBRG-14) virus and monitored daily for weight loss and mortality. The percentages of survival rate and
changes of body weight and temperature were recorded. (A) Survival for H5N1-VLP groups, (B) survival for IWV groups, Mice that lost greater than
30% body weight were euthanized. (C) Body weight and temperature for H5N1-VLP groups. For th groups receiving 0.3 mg and 1.5 mg antigen dose,
only data of surviving mice are shown. (D) Body weight and temperature for IWV groups.
doi:10.1371/journal.pone.0009784.g008
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Proteins separated in one-dimensional polyacrylamide gels were
sequentially isolated and subjected to in gel tryptic digestion prior
to mass spectrometric analysis. Briefly, the protein bands from the
1-D gel were manually excised from the gel and cut into small
pieces (,0.5 mm
3). The gel pieces were washed in a microcen-
trifuge tube with a solution containing 50% methanol and 5%
acetic acid for 2–3 h, twice with a solution of 25 mM NH4HCO3
in 50% acetonitrile for 10 min each, and then dried in a vacuum
centrifuge. After DTT reduction and iodoacetamide alkylation, a
solution containing 75 ng of sequencing grade modified trypsin
(Promega Corporation, Madison, WI) in 25 mLo f2 5 m M
NH4HCO3 was added and incubated with dried gel pieces for
12–16 h at 37uC. Following digestion, tryptic peptides were
extracted twice for 15 min each with 50% acetonitrile containing
5% formic acid under vortexing. The extracted solutions were
pooled and evaporated to dryness under vacuum. The dried pellet
was re-dissolved in 10–20 mL of 0.1% formic acid for LC/MS/MS
analysis as described below. The NanoLC2nanoESi-MS/MS
analysis was performed on a nanoAcquity system (Waters, Milford,
MA) connected to an LTQ-Orbitrap XL hybrid mass spectrom-
eter (Thermo Electron, Bremen, Germany) equipped with a
PicoView nanospray interface (New Objective, Woburn, MA).
Peptide mixtures were loaded onto a 75 mm625 cm BEH C18
column (Waters) packed with 1.7 mm particles with a pore size of
130 A ˚ and were separated using a segmented gradient from 5% to
50% solvent B (acetonitrile with 0.1% formic acid) over 90 min at
a flow rate of 300 nL/min and a column temperature of 35uC.
Solvent A was 0.1% formic acid in water. The mass spectrometer
was operated in the data-dependent mode. Briefly, survey full-scan
MS spectra were acquired in the orbitrap (m/z 350–1600) with the
resolution set to 60,000 at m/z 400 and automatic gain control
(AGC) target at 106. The 10 most intense ions were sequentially
isolated for CID MS/MS fragmentation and detection in the
linear ion trap (AGC target at 7000) with previously selected ions
dynamically excluded for 90 s. Ions with single and/or unrecog-
nized charge state were also excluded. The MS and MS/MS raw
data were processed with Bioworks 3.3.1 and searched against an
in-house generated NCBI protein database using Mascot Daemon
2.2 server. Search criteria used were trypsin digestion, variable
modifications set as carbamidomethyl (C) and oxidation (M),
allowing up to 2 missed cleavages, mass accuracy of 10 ppm on
the parent ion and 0.60 Da on the fragment ions.
Virus propagation, hemagglutination, and serological
tests
Influenza virus A/Taiwan/083/2006 and H5N1 (NIBRG-14)
strains (National Institute for Biological Standards and Control,
Potters Bar, U.K.) were propagated in Vero (for VLP comparison)
or MDCK cells (for viral challenge). To assess hemagglutination,
3.5 mg of VLPs or virus and their serial 2-fold dilutions were mixed
with a 0.75% suspension of guinea pig red blood cells in 96 well
plates. Plates were incubated for 1 h and hemagglutination was
assessed by eye. The highest dilution of VLPs or virus giving
hemagglutination was determined as 1 HA unit.
To assess hemagglutination inhibition (HI) titers, sera were
treated with a receptor-destroying enzyme and heat-inactivated
(30 min, 56uC), tested in 2-fold dilutions starting with an initial
dilution of 1:10, then mixed with 8 HA units of H5N1-VLP and
incubated at room temperature. After 1 h, a 0.75% suspension of
guinea pig red blood cells was added and hemagglutination was
assessed 2 h later by eye. HI titer is expressed as the reciprocal of
the highest dilution that showed 50% inhibition of hemagglutina-
tion. All samples were tested in triplicate.
ELISA plates (Nunc) were coated with indicated H5 glycopro-
tein, VLPs, or virus at 4uC overnight and blocked with 1% casein
(Blocker Casein, Pierce, Rockford, IL) in PBS. ELISA plates were
then incubated with serum samples of indicated dilution for 1 h at
37uC, traced with HRP-conjugated secondary Ab, and developed
with TMB substrate (Pierce). They were washed with PBST five
times between each step of ELISA. Finally, for the ELISA readout,
the absorbance of each well at 450 nm wavelength (A450) was
measured using a microplate reader (Power Wave XS, Bio-Tek).
Vaccination and viral challenge
Female BALB/c mice (6 weeks old) were purchased from the
National Laboratory Animal Center, and randomly assigned to
receive two doses of vaccine 21 days apart. Vaccines of 0.3 mg,
1.5 mg, 2.5 mg, or 10 mg H5N1-VLPs comprised of either
0.054 mg, 0.27 mg, 0.45 mg, or 1.8 mg of H5 glycoprotein, and
whole virus vaccine were grown in chicken embryo, inactivated by
formalin and applied at 2.5 mgo r1 0mg doses. Vaccines or PBS (as
mock control) were given by intramuscular injection into the
quadriceps. Blood was collected from mice via the retro-orbital
sinus, transferred to a tube containing a serum separator and clot
activator, and allowed to clot at room temperature. Sera were
removed after centrifugation and stocked at 280uC. The
immunized mice were challenged intranasally with a recombinant
H5N1 virus, NIBRG-14, with a lethal dose (100-fold lethal dose to
50% of mice) as performed previously [48]. The mice were
monitored daily for 14 days after the challenge for survival and
morbidity (i.e. weight loss, inactivity and body temperature). All
animal experiments were evaluated and approved by the
Institutional Animal Care and Use Committee of Academia
Sinica.
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